Sirolimus interferes with iron homeostasis in renal transplant recipients

被引:66
作者
Maiorano, Annamaria
Stallone, Giovanni
Schena, Antonio
Infante, Barbara
Pontrelli, Paola
Schena, Francesco Paolo
Grandaliano, Giuseppe
机构
[1] Univ Bari, Div Nephrol, Dept Emergency & Transplantat, I-70124 Bari, Italy
[2] Univ Foggia, Div Nephrol, Dept Biomed Sci, Foggia, Italy
关键词
sirolimus; anemia; renal transplantation; hepcidin;
D O I
10.1097/01.tp.0000235545.49391.1b
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Sirolimus is an immunosuppressive drug whose use is frequently associated with anemia. A pathogenic link between sirolimus-induced anemia and the appearance of an inflammatory state was recently suggested. Because inflammation-related anemia is characterized by a functional iron deficiency, we investigated whether sirolimus may influence iron homeostasis and serum levels of hepcidin, a key mediator of inflammation-related-anemia. Methods. To this purpose, 42 consecutive transplanted patients with biopsy-proven chronic allograft nephropathy were randomized (2:1 ratio) to receive either a 40% cyclosporine reduction (group A, 14 patients) or immediate cyclosporine withdrawal and sirolimus introduction (group B, 28 patients). Hemoglobin levels and iron status were evaluated 6 months before and after randomization. Results. The two groups had similar hemoglobin levels and iron status at baseline. We did not observe any significant change in hemoglobin and iron status in group A patients after randomization. On the contrary, we observed a significant reduction of hemoglobin without any change of red blood cell count after sirolimus introduction, with a significant reduction of mean corpuscular volume and mean corpuscular hemoglobin. Serum iron and transferrin saturation (TSAT) levels were markedly reduced after the switch, while ferritin serum concentrations remained stable. Although sirolimus-induced anemia was recently suggested to resemble inflammation-related anemia, hepcidin serum levels were similar in the two groups after randomization. None of group A and eight of group B patients presented a TSAT < 20 and were given iron supplementation after randomization, in all of them oral iron therapy did not influence either hemoglobin or serum iron levels. Conclusion. We demonstrated that sirolimus-induced anemia is independent of the drug antiproliferative effect and does not present the features of inflammation-related anemia. This event maybe due to the direct influence of sirolimus on iron homeostasis.
引用
收藏
页码:908 / 912
页数:5
相关论文
共 30 条
[1]   Chemistry and biology of eukaryotic iron metabolism [J].
Aisen, P ;
Enns, C ;
Wessling-Resnick, M .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2001, 33 (10) :940-959
[2]   A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt [J].
Aoki, M ;
Blazek, E ;
Vogt, PK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (01) :136-141
[3]   Starvation induces vacuolar targeting and degradation of the tryptophan permease in yeast [J].
Beck, T ;
Schmidt, A ;
Hall, MN .
JOURNAL OF CELL BIOLOGY, 1999, 146 (06) :1227-1237
[4]  
EBPG Expert Group on Renal Transplantation, 2002, ANAEMIA NEPHROL D S4, V17, P48
[5]   Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake [J].
Edinger, AL ;
Thompson, CB .
MOLECULAR BIOLOGY OF THE CELL, 2002, 13 (07) :2276-2288
[6]   Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation [J].
Ganz, T .
BLOOD, 2003, 102 (03) :783-788
[7]   Sirolimus (rapamycin)-based therapy in human renal transplantation -: Similar efficacy and different toxicity compared with cyclosporine [J].
Groth, CG ;
Bäckman, L ;
Morales, JM ;
Calne, R ;
Kreis, H ;
Lang, P ;
Touraine, JL ;
Claesson, K ;
Campistol, JM ;
Durand, D ;
Wramner, L ;
Brattström, C ;
Charpentier, B .
TRANSPLANTATION, 1999, 67 (07) :1036-1042
[8]  
KAHAN BD, 2000, CLIN TRANSPLANT, V18, P145
[9]   Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients [J].
Kreis, H ;
Cisterne, JM ;
Land, W ;
Wramner, L ;
Squifflet, JP ;
Abramowicz, D ;
Campistol, JM ;
Morales, JM ;
Grinyo, JM ;
Mourad, G ;
Berthoux, FC ;
Brattström, C ;
Lebranchu, Y ;
Vialtel, P .
TRANSPLANTATION, 2000, 69 (07) :1252-1260
[10]   A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts [J].
MacDonald, AS .
TRANSPLANTATION, 2001, 71 (02) :271-280